Pharmaceuticals have a new
shortcut to market, and it could be right through your patent. Whether you want
to explore this path or try to block your competitor from taking it, you need to
be familiar with the pairing of Inter Partes Review (IPR) created by the America
Invents Act, with the submission of a 505(b)(2) new drug application. The newly
created IPR procedure can reduce the cost of paying the patent tolls necessary
for utilizing the 505(b)(2) approval pathway. James Zak, Patent Attorney shows
you how this new pathway works.
This CLE is available online
until April 14, 2017.
Presenter:
James
Zak, Antonelli, Terry, Stout &
Kraus
CLE Credits:
1.0 Standard CLE
credit approved | Event Code: 203807
Cost:
MSBA Members: $29.95
Non-MSBA Members:
$49.95